Public Sector Pension Investment Board Purchases 25,718 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Public Sector Pension Investment Board grew its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 5.8% during the second quarter, HoldingsChannel reports. The institutional investor owned 470,667 shares of the company’s stock after purchasing an additional 25,718 shares during the period. Public Sector Pension Investment Board’s holdings in Teva Pharmaceutical Industries were worth $7,648,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in TEVA. Janney Montgomery Scott LLC lifted its stake in Teva Pharmaceutical Industries by 13.6% during the 1st quarter. Janney Montgomery Scott LLC now owns 1,372,477 shares of the company’s stock valued at $19,366,000 after acquiring an additional 164,614 shares during the period. QRG Capital Management Inc. boosted its holdings in Teva Pharmaceutical Industries by 53.7% in the first quarter. QRG Capital Management Inc. now owns 143,747 shares of the company’s stock worth $2,028,000 after purchasing an additional 50,247 shares during the last quarter. Capital Wealth Planning LLC bought a new stake in Teva Pharmaceutical Industries in the 1st quarter worth approximately $2,169,000. Public Employees Retirement Association of Colorado raised its stake in Teva Pharmaceutical Industries by 1,382.8% during the 4th quarter. Public Employees Retirement Association of Colorado now owns 255,826 shares of the company’s stock valued at $2,671,000 after buying an additional 238,573 shares during the last quarter. Finally, SG Americas Securities LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 12.0% during the 1st quarter. SG Americas Securities LLC now owns 610,407 shares of the company’s stock valued at $8,613,000 after buying an additional 65,529 shares during the period. Institutional investors own 54.05% of the company’s stock.

Analyst Ratings Changes

Several analysts recently commented on TEVA shares. Argus raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 price objective for the company in a report on Wednesday, July 10th. Barclays boosted their price target on Teva Pharmaceutical Industries from $21.00 to $22.00 and gave the company an “overweight” rating in a research note on Thursday, August 1st. StockNews.com downgraded shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Monday. Jefferies Financial Group upped their target price on shares of Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the company a “buy” rating in a report on Thursday, June 27th. Finally, Bank of America lifted their price target on shares of Teva Pharmaceutical Industries from $18.00 to $21.00 and gave the stock a “buy” rating in a research note on Thursday, May 30th. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $18.89.

Teva Pharmaceutical Industries Trading Up 0.1 %

Shares of Teva Pharmaceutical Industries stock opened at $17.73 on Wednesday. The company has a fifty day moving average of $17.70 and a 200 day moving average of $16.16. Teva Pharmaceutical Industries Limited has a fifty-two week low of $8.06 and a fifty-two week high of $19.08. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 2.52.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Wednesday, July 31st. The company reported $0.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.55 by $0.03. Teva Pharmaceutical Industries had a negative net margin of 2.73% and a positive return on equity of 39.66%. The firm had revenue of $4.16 billion for the quarter, compared to analysts’ expectations of $3.99 billion. On average, equities analysts forecast that Teva Pharmaceutical Industries Limited will post 2.33 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Eric A. Hughes sold 24,537 shares of the firm’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $17.25, for a total transaction of $423,263.25. Following the completion of the transaction, the insider now owns 45,060 shares in the company, valued at $777,285. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 0.55% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.